CERV-186 Cells

The CERV-186 cell line, derived in vitro from the xenotransplant of cervical carcinoma MRI-H-186, serves as a biological model for invasive, large-cell, non-keratinizing squamous cell carcinoma. This cell line was established and adapted for in vivo transplantation under the direction of Dr. Bodgen at the Mason Research Institute. Characterized by its genomic properties, MRI-H186 contains approximately 26 integrated copies of both full-length and truncated forms of the HPV16 genome, which significantly influence its transcriptomic profile. MRI-H186 cells are distinguished by their robust expression of both full-length and truncated early HPV16 transcripts, notably displaying high levels of E5 full-length (fl) RNA. This transcriptional signature is notably distinct from that observed in other cervical carcinoma cell lines such as CaSki and MRI-H196. Additionally, the transcriptional activity of MRI-H186, in terms of the expression of various other transcripts, shows a close alignment with the patterns observed in the HPK-IA and C3 cell lines, indicating a similar transcriptional behavior across these models. The presence of both full-length and truncated HPV16 genomic integrations in MRI-H186 cells is a key factor in their vigorous expression of early viral transcripts, particularly underscored by the significant expression of E5 fl RNA. This intense transcriptional activity culminates at the early polyadenylation signal, highlighting the unique transcriptional dynamics within the MRI-H186 cell line. Reproductive system cancer cell lines, Cervix, Squamous cell carcinoma, Growth Conditions: Adherent, Biosafety level: BSL 2